|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Association of variants in HTRA1 and NOTCH3 with MRI-defined extremes of cerebral small vessel disease in older subjects.
|
30859180 |
2019 |
|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
|
|
|
|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We recently demonstrated that mutations in the high-temperature requirement A (HTRA) serine peptidase 1 (HTRA1) gene cause a hereditary cerebral small-vessel disease, cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL).
|
21320870 |
2011 |
|
Cerebral Small Vessel Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Therefore, HTRA1 represents another new gene to be considered in future studies of cerebral small-vessel diseases, as well as alopecia and degenerative vertebral/disk diseases.
|
21215656 |
2011 |
|
Cerebral Small Vessel Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Screening of HTRA1 should be considered in patients with familial CSVD.
|
29305662 |
2018 |
|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease.
|
26063658 |
2015 |
|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thus, the CADASIL-like family disease may be caused by heterozygous HTRA1 gene mutation, which leads to autosomal dominant hereditary cerebral small vessel disease.
|
29561953 |
2018 |
|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recently, clinical studies have indicated that some patients with heterozygous mutations in HTRA1 may also suffer CSVD.
|
29797751 |
2018 |
|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Heterozygous mutations of HTRA1 gene in patients with familial cerebral small vessel disease.
|
28782182 |
2017 |
|
Cerebral Small Vessel Diseases
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To elucidate the molecular mechanism of mutant HTRA1-dependent cerebral small vessel disease in heterozygous individuals.
|
27164673 |
2016 |
|
Cerebral Small Vessel Diseases
|
0.500 |
Biomarker
|
group |
BEFREE |
Cerebral small vessel disease-related protease HtrA1 processes latent TGF-β binding protein 1 and facilitates TGF-β signaling.
|
25369932 |
2014 |
|
Cerebral Small Vessel Diseases
|
0.500 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease.
|
26063658 |
2015 |
|
Lung Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.
|
27935865 |
2017 |
|
Lung Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Analysis of HtrA1 serine protease expression in human lung cancer.
|
17094466 |
2006 |
|
Cerebrovascular accident
|
0.110 |
Biomarker
|
group |
BEFREE |
Also reviewed is recent progress in understanding single-gene disorders in which stroke is a major feature of the phenotype, including CADASIL, CARASIL, hereditary angiopathy with nephropathy, aneurysm and muscle cramps, and Fabry disease and progress in pharmacogenomics as it relates to response to antiplatelet therapy.
|
21058051 |
2011 |
|
Cerebrovascular accident
|
0.110 |
GeneticVariation
|
group |
GWASCAT |
Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.
|
29531354 |
2018 |
|
Cerebrovascular accident
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Leukoencephalopathy
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Leukoencephalopathy
|
0.110 |
GeneticVariation
|
group |
BEFREE |
Leukoencephalopathy and small vessel disease without any risk factors is a significant finding for the differential diagnosis of HTRA1 gene pathology.
|
31494012 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The serine protease HTRA1 is involved in several vascular diseases and its expression is often deregulated in cancer.
|
29713059 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The HTRA1 gene encoding an evolutionary conserved protein quality-control factor can be epigenetically silenced or inactivated by mutation under pathologic conditions such as cancer.
|
29863874 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging evidence has demonstrated that high-temperature requirement protein A1 (HtrA1) appears to be involved in several important biological processes in mammals such as growth, apoptosis, embryogenesis, invasion, metastasis, and cancer and has been verified to be reduced in a variety of human tumors.
|
23079781 |
2013 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In A549 cells, stable knockdown of HtrA1 expression promoted cancer stem cell-like properties and CDDP insensitivity, however, these effects were blocked by inhibition of PI3K/Akt pathway using LY294002.
|
24356998 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High temperature requirement factor A1 (HtrA1) plays an important role in cancer cell proliferation, migration, apoptosis, and differentiation.
|
30484491 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate the implication of HtrA proteins in thyroid carcinogenesis suggest that HtrA3 variants may play different roles in cancer development, and that the increased HtrA3-L levels in thyroid tissue could be correlated with the development of malignant lesions.
|
22923201 |
2012 |